OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has shown significant progress in the clinical development of urcosimod, a promising therapeutic for managing pain related to inflammatory eye diseases. Notably, clinical trial results indicate that 67% of patients receiving the 0.05% urcosimod formulation experienced more than a 50% improvement in pain, compared to only 33% in the placebo group, with a marked reduction in pain scores observed as early as Week 4. These compelling outcomes underscore the potential efficacy of urcosimod, providing a solid foundation for OKYO Pharma's growth trajectory in the biopharmaceutical market.

OKYO Pharma Ltd reported a net loss of $4.7 million for the fiscal year ending March 31, 2025, translating to a loss of $0.12 per share. The company's 0.05% urcosimod group exhibited concerning clinical trial data, with all patients reporting moderate to severe pain scores, contrasting sharply with the placebo group's predominantly mild scores. Additionally, a range of significant risks, including potential clinical trial failures, challenges in securing regulatory approval, and concerns regarding commercial success and shareholder dilution, contribute to a negative outlook for the company's stock.